Table 2.

Percentage of adverse effects related to the genotypes and alterations in body composition following antiviral treatment.

Adverse effects	HCV genotype 1 (n = 15)	HCV genotype 3 (n = 22)
Cephalgia	8/15 (53.3%) *	8/22 (36.3%)
Fatigue	13/15 (86.6%) *	12/22 (54.5%)
Flu-like symptoms	10/15 (66.6%)	18/22 (81.8%) *

Symptoms of fatigue and cephalgia were more evident in patients with genotype 1 whereas flu-like symptoms were more present in patients with genotype 3 following antiviral treatment (* p < 0.05).